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1. Introduction
Ca2+ ions form important intracellular messenger molecules in nearly every cell type of the
human body. Under so-called “resting“ states of the cell, the concentration of Ca2+ in the cy‐
toplasm is extremely low (~10-7M), but this can rapidly rise ~2 orders of magnitude when an
appropriate signal is generated. Ca2+ ions can enter the cytoplasm either from the extracellu‐
lar space or from intracellular compartments, through specialized membrane proteins.
These "calcium channels" are complex proteins, often consisting of multiple subunits, and
are targets for multiple regulatory events.
A major intracellular Ca2+ store is the endoplasmic reticulum (ER), or its specialized form, the
sarcoplasmic reticulum (SR) in muscle tissue. The mobilization of Ca2+ from these organelles
can trigger many Ca2+-dependent events, such as the contraction of muscle tissue. The coupling
between electrical excitation of a muscle cell and its subsequent contraction (excitation-con‐
traction coupling, E-C coupling) is a finely orchestrated process that requires a functional
cross-talk between proteins embedded in the plasma membrane and in the SR membrane (Fig‐
ure 1). An electrical signal, a depolarization of the plasma membrane, can lead to opening of L-
type  voltage-gated  calcium  channels  (CaV),  which  results  in  the  influx  of  Ca2+  into  the
cytoplasm. In the SR membrane, large calcium release channels called Ryanodine Receptors
(RyRs) can detect this initial influx, and release more Ca2+ in a process known as Ca2+-induced
Ca2+ release (CICR). The latter event provides the bulk of the Ca2+ required for contraction to oc‐
cur. In this scenario, the RyRs form signal amplifiers, which both detect and augment the Ca2+
signal [1, 2]. This scenario likely predominates in cardiac tissue, but Ca2+ is not always required
to open RyRs. In skeletal muscle, for example, various pieces of evidence suggest a direct inter‐
action between the L-type calcium channel (CaV1.1) and the RyR [3-6]. In this case, the depolari‐
© 2013 Yuchi et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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zation of the plasma membrane causes distinct conformational changes in CaV1.1, which are
then transmitted directly to the RyR, causing them to open.
Figure 1. Schematic diagram of components in E-C coupling. Depolarization of plasma membrane (PM) activates the
embedded voltage-gated calcium channel (CaV) which conducts Ca2+ influx into the cytoplasm. RyRs in SR membrane
sense this Ca2+ signal and amplify it by releasing more Ca2+ from SR store (Ca2+ -induced Ca2+ release, CICR). This will
provide enough Ca2+ for the muscle contraction to occur. SERCA pump in the SR and Na+-Ca2+ exchanger in the PM
pump out the Ca2+ from cytoplasm and restore the resting [Ca2+]. The activity of RyR can be upregulated by the PKA
phosphoryaltion upon the activation of β-adrenergic receptor on the PM.
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RyRs owe their name to the binding of ryanodine, a toxic compound from the South Ameri‐
can plant Ryania speciosa [7]. RyRs are currently the largest known ion channels, with a mas‐
sive size of >2.2MDa. They form homotetrameric assemblies [8, 9], and each monomer
contains ~5000 amino acid residues. In humans and all other mammalian organisms investi‐
gated so far, three different isoforms (RyR1-3) have been found to date. RyR1 is widely ex‐
pressed in skeletal muscle, and was the first one to be cloned [10, 11]. RyR2 is primarily
found in the heart [12, 13] and RyR3 was originally identified in the brain [14], although
each isoform is found in many different cell types [15].
Since Ca2+ ions form very potent intracellular messenger molecules, it is not surprising that
their entry into the cytoplasm is under intense regulation. RyRs therefore form the targets
for a plethora of auxiliary proteins and small molecules that are known to regulate their
ability to open or close [15-17]. The primary regulatory molecule is cytoplasmic Ca2+, which
triggers the channel to open. However, higher Ca2+ levels can trigger closing, indicating that
there is more than one Ca2+ binding site. Under conditions whereby the SR is overloaded
with Ca2+, RyRs can also open spontaneously in a process known as store-overload-induced
calcium release (SOICR) [18, 19].
An overview of several positive and negative RyR modulators is shown in Figure 2. Well-
known regulators include FK506 binding proteins (FKBPs), small proteins that stabilize the
closed state of the channels and can prevent the formation of subconductance states [20, 21].
Calmodulin (CaM) is a ~17kDa protein that can bind 4 Ca2+ ions in separate EF hands, well-
known Ca2+-binding motifs. CaM binds RyR in a 4:1 stoichiometry and can either inhibit or
stimulate RyRs depending on the isoform and Ca2+ levels [22-25]. RyRs are also the target for
several kinases (PKA, PKG, CaMKII) and phosphatases (PP1, PP2A, PDE4D3), and the de‐
gree of phosphorylation seems to affect RyR activity [26]. In this chapter, we discuss the in‐
volvement of RyRs in several genetic diseases, summarize the outcome of several years of
functional studies on disease variants of the RyR, and describe the insights into disease
mechanisms through low- and high-resolution structural studies.
2. Ryanodine receptors and genetic disease
2.1. Malignant hyperthermia
Malignant hyperthermia (MH) is a pharmacogenetic disorder, requiring both a genetic mu‐
tation and an external trigger to cause a disease phenotype. The condition is mostly linked
to mutations in the RyR skeletal muscle isoform (RyR1), but some mutations in the skeletal
muscle L-type calcium channel (CaV1.1) can also cause MH [27]. It is typically triggered by
the use of inhalational anesthetics or succinylcholine, a muscle relaxant [28]. The condition is
considered rare, with an incidence of 1:60,000 for adults or 1:15,000 for children [29]. An MH
episode is characterized by an abnormal rise in the core body temperature, skeletal muscle
rigidity, acidosis, and tachycardia. Most modern surgery rooms monitor for these signs, and
will make use of dantrolene, which can rapidly reverse the symptoms. Dantrolene acts by
decreasing the intracellular Ca2+ concentration [30]. Several studies suggest a direct interac‐
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tion between dantrolene and RyR1, and it is thought that dantrolene directly prevents Ca2+
release through RyR1 [31, 32].
The first link between MH and RyR1 came through a related disorder in pigs, known as por‐
cine stress syndrome (PSS). It was found that the pig RyR1 mutation R615C underlies PSS
[33], and soon after the corresponding mutation in humans was linked to MH [34].
Figure 2. Regulation of RyRs. RyRs are regulated by a number of postive and negative modulators from both the cyto‐
plasmic and SR luminal sides. S100A1: S100 calcium-binding protein A1; NO: nitric oxide; PKA: cAMP-dependent pro‐
tein kinase; PKG: cGMP-dependent protein kinase; CaMKII: Ca2+/calmodulin-dependent protein kinase II; DHPR:
dihydropyridine receptor/L-type voltage-dependent calcium channel; GSH: glutathione; GSSG: glutathione disulfide;
FKBP12/12.6: FK506 binding protein 12/12.6; PP1: protein phosphatase 1; PP2A: protein phosphatase 2; PDE4D3:
cAMP-specific 3',5'-cyclic phosphodiesterase 4D3.
2.2. Core myopathies
Central core disease (CCD) is a congenital myopathy, characterized by progressive muscle
weakness and the presence of metabolically inactive tissue (cores) in the center of muscle fi‐
bers. These cores lack mitochondria and the myofibrillar organization is disrupted. The
common phenotype of CCD includes muscle atrophy, floppy infant syndrome and skeletal
muscle deformities [35, 36]. It was found early on that there is a connection between CCD
and MH susceptibility [37], and some RyR1 mutations have been found to cause both. Mul‐
ti-mini core disease (MmD) is another inherited congenital myopathy. Different from CCD,
whose inheritance is autosomal dominant, MmD is usually considered recessive [35]. As its
name suggests, MmD is characterized by the presence of multiple not-well-defined cores in
muscle fibers. MmD can cause axial muscle weakness that can lead to severe scoliosis [35].
Although MmD is mainly associated with mutations in RyR1 [38], mutations in selenopro‐
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tein N 1 [39], a protein required for RyR1 calcium release [40], and α-actin (ACTA1) [41]
have also been found to underlie MmD.
2.3. Catecholaminergic polymorphic ventricular tachycardia
Also known as CPVT, this disorder manifests itself in young individuals, with either syn‐
cope or sudden cardiac death as the first symptom. Many affected individuals will develop
cardiac arrhythmias that are triggered by exercise or emotional stress. CPVT is mostly de‐
tected through stress tests, which indicate bidirectional ventricular tachycardia. Typically no
morphological abnormalities of the myocardium are detected. The disease is mostly due to
mutations in the cardiac RyR2 isoform [42], but mutations in the associated proteins calse‐
questrin [43] and triadin [44] can also be the cause. As CPVT is triggered by β-adrenergic
stimulation, it can be treated by β-blockers [45]. Flecainide, a sodium channel blocker, has
also been found to be beneficial for CPVT patients [46].
Now more than 20 years since the initial identification of the first RyR disease mutations,
nearly 500 mutations have been found in RyR1 and RyR2 combined. In RyR1, most disease
mutations seem to be spread across the gene, with some clustering in distinct areas, whereas
in RyR2, most mutations are found in one of 3 or 4 different disease hot spots (Figure 3). The
appearance of clusters may be due to bias in sequencing, as historically only the areas that
had already shown to be involved in disease were being considered for sequence analysis.
Figure 3. Disease hot spots. Linear view of the RyR1 and RyR2 sequences with each vertical line representing a disease
mutation. The areas of solid colors correspond to domains A(blue), B (green), C (red), SPRY (orange), Tandem Repeat
domains (Rep) (purple) and Pore-forming domain (PF) (pink).
3. Functional studies
Although increasing numbers of RyR mutations are identified in patients and their family
members, only a handful of them have been validated as causative disease mutations [29].
Functional studies are necessary to prove the molecular basis of the mutations as pathogen‐
ic. Without functional characterizations, the possibility that the mutations are the result of
polymorphism cannot be ruled out. In this section, different methods of performing func‐
tional studies and their results are highlighted.
Structural Insights Into Disease Mutations of the Ryanodine Receptor
http://dx.doi.org/10.5772/53641
109
3.1. Model systems
There are a variety of ways to prepare model systems to study functional effects of muta‐
tions in RyRs: endogenous or recombinant expression systems and in vivo models.
In the early days, before and shortly after the discovery of RyR mutations in MH-susceptible
pigs and individuals, SR vesicles were prepared from muscle biopsies [47-55]. SR vesicles
from non-MH-susceptible animals or individuals were also obtained to serve as controls.
These are endogenous expression systems since SR vesicles contain RyRs, and therefore, can
be used as a whole or can be further purified to obtain single RyR channels. These ap‐
proaches can be invasive, as they involve acquisition of native RyRs expressed in patients or
knock-in mice carrying mutations. For example, skeletal myotubes have been isolated from
MH-susceptible and/or CCD patients [56-59]. Both RyR1 and RyR2 can be studied by isolat‐
ing skeletal myotubes and cardiomyocytes from knock-in mice, respectively [60-73]. Flexor
digitorum brevis fibers, present in the feet, have also been derived from knock-in mice for
the study of RyR1 mutations [67, 74-76]. In some cases, measures have been taken to allevi‐
ate some of the affliction on obtaining native RyRs from patients by using less invasive ap‐
proaches. In one study of a CCD-associated RyR1 mutation, fibroblasts from a CCD patient
were differentiated into muscle by myoD conversion with adenovirus [77]. In other cases,
immortalized lymphoblastoid cells were generated using B-lymphocytes isolated from
blood samples [78-83].
A more commonly used model is a recombinant expression system. By using cells that lack
the native expression of RyRs, all results will arise only from the mutant RyR. One of the
most commonly used systems are dyspedic myotubes, which are derived from mice that
lack RyR1, called "RyR1-null mice" [80, 84-90]. Also commonly used are human embryonic
kidney (HEK)-293 cells. HEK-293 cells not only lack native RyR expression but also lack oth‐
er complexes involved in E-C coupling and yet have been demonstrated to express function‐
al RyR when its cDNA is transfected [19, 79, 80, 89-115]. Other cell lines used in functional
studies include COS-7 [116], myoblastic C2C12 [117], HL-1 cardiomyocytes [108, 110, 115,
118], and CHO cells [119].
Finally, knock-in mice have served as valuable models for the study of mutations in RyR1
and RyR2 [60-64, 66-76, 120-128]. The comparison between mice that are homozygous or
heterozygous for the mutation in question has provided clues about the gene dosage effects.
Studying the effect of mutations on the body as a whole provides insights that are more rele‐
vant to clinical phenotypes.
3.2. Methods
Multiple techniques have been implemented to study mutant RyRs from different expres‐
sion systems. Five major methods are introduced here.
One way to measure Ca2+ release through RyR channels is through [45Ca2+]-uptake and -re‐
lease assays [50, 52, 98].  Microsomal vesicles expressing recombinant RyR and SERCA1a
are prepared. The vesicles are then incubated with 45Ca2+, during which SERCA1a pumps
45Ca2+  into the vesicles. By comparing the amount of 45Ca2+  accumulation in the presence
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or  absence  of  the  potent  RyR  inhibitor  Ruthenium  Red,  the  amount  of  Ca2+  release
through RyR can be determined.
A more widely used technique is a Ca2+ fluorescence assay involving whole cell samples
(Figure 4A,B) [19, 57-59, 70, 71, 73, 77, 79, 89, 91-93, 95, 102, 104-106, 108, 109, 112, 113,
115-118]. Cells with either endogenous or recombinant expression of RyR are loaded with a
fluorescent Ca2+ indicator, such as fura-2, which diffuses throughout the cytoplasm. By
measuring fluorescence with confocal microscopy, resting [Ca2+] levels in the cytoplasm, as
well as frequency, duration, and extent of Ca2+ release from RyR can be calculated.
Commonly used is a [3H]ryanodine binding assay (Figure 4C) [19, 51, 54, 60, 67, 77, 79, 86,
90, 92, 93, 95, 96, 103, 105, 108, 113, 129]. SR vesicles containing endogenous or recombinant
RyR are incubated with radioactive [3H]ryanodine. Since ryanodine binds to the channels in
the open state, binding of [3H]ryanodine is indicative of the measure of open channels. The
extent of RyR activation is then measured by radioactive counting.
As opposed to whole-cell measurements, activities of a single channel can be recorded us‐
ing planar  lipid bilayer  electrophysiology (Figure  4D)  [19,  53,  54,  67,  69,  77,  79,  99-101,
105, 107, 108, 111, 112, 114]. Recombinant or endogenous RyR from crude SR vesicle prep‐
arations or from purified material are fused into an artificial lipid bilayer formed across
two chambers.  The  current  generated by  ions  passing through the  channel  is  recorded.
This method allows various properties of the single channel to be determined, including
the  open probability,  duration  of  the  open and closed time,  and conductance.  The  two
chambers can resemble cytoplasmic and luminal sides of the channel, allowing the studies
of Ca2+-induced Ca2+  release (CICR) from the cytoplasmic side or store-overload-induced
Ca2+ release (SOICR) from the luminal side. The planar lipid bilayer technique also allows
for additional control because purified auxiliary proteins or pharmacological modulators
can be added to either side.
3.3. Highlight of the results
Functional studies of mutant RyR channels have generated multitudes of insights into the
molecular  basis  of  the  RyR  channelopathies.  Accordingly,  complex  sets  of  results  have
been generated that require careful interpretation and have resulted in a lot of debate. For
example, many mutations seem to make the RyR channels more active, but the exact na‐
ture of this change is still under scrutiny. In some cases, mutations seem to be more sensi‐
tive  to  cytosolic  activators,  while  other  evidence  suggests  they  are  more  sensitive  to
luminal Ca2+  levels.  Others suggest that altered phosphorylation states of the channel or
affinity  to  auxiliary proteins  is  the  causative mechanism.  For  this  section,  results  of  the
functional studies are highlighted as mutations that cause RyRs to be either hypersensi‐
tive (more prone to open upon stimulation) or hyposensitive (requiring more stimulus to
open). RyR mutations can be pathogenic either through hyper- or hypo-activity since al‐
teration in Ca2+  homeostasis in either direction can cause aberrant muscle functions.  Yet
other  mutations  have  exhibited  no  apparent  alterations  in  the  functional  studies  per‐
formed so far. The results are summarized in Table 1.
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Figure 4. Representative figures from exemplary functional studies. (A) Single-cell fluorescent Ca2+ images of HEK-293
cells expressing RyR2 WT and A4860G at various extracellular [Ca2+] (top) and fura-2 ratios of representative RyR2 WT
and A4860G cells (bottom)[110]. (B) Representative single-cell fluorescent traces of Ca2+ release stimulated by incre‐
mental doses of caffeine in dyspedic myotubes transfected with RyR1 WT and mutants cDNAs (top) and correspond‐
ing sigmoidal dose-response curves (bottom)[86]. (C) [3H]ryanodine binding assay on SR vesicles from MHN
(malignant-hyperthermia non-suceptible, or RyR1 WT) and MHS (malignant-hyperthermia suceptible, or RyR1
G2434R) individuals in presence of caffeine (left) and 4-CmC (right)[55]. (D) Single-channel activities of RyR2 WT and
N4104K recorded in planar lipid bilayers with luminal [Ca2+] of 45nM (a) or 300nM (b). Downward strokes in the cur‐
rent traces denote channel-opening events[19].
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Effect Isoform Mutations Disease References Mutations Disease References
Hyperactive
RyR1
C35R MH [91, 94] R2355W MH [58]
R163C MH/CCD/MmD [61, 65-67, 85, 86, 91, 94,
103]
E2371G MH [82]
G2375A MH [58]
G248R MH [91, 94, 103] G2434R MH [1,2,36]
R328W MH [97] R2435H MH/CCD [85, 91, 94]
G341R MH [86, 91, 94] R2435L MH/CCD [77, 88]
H382N MH [83] I2453T MH/CCD [57]
I403M MH/CCD [91, 94] R2454H MH/CCD [82]
Y522S MH/CCD [60, 63, 64, 85, 87, 89, 91,
94, 120]
R2458C MH [91, 94]
R2458H MH [86, 91, 94]
R530H MH [82] R2458H/R3348C MH [59]
R552W MH [91, 94] R2508C MH/CCD [102]
A612P MH [59] R2508G MH [83]
R614C MH [47-52, 54, 86, 88, 89, 91,
94, 101, 116, 117, 129]
ΔR4214_F4216 CCD [80]
T4637A CCD [88]
R614L MH [91, 94] Y4796C CCD [87, 88]
E1058K MH [83] T4826I MH [76, 86, 103, 122]
K1393R MH [83] H4833Y MH [81, 103]
R1679H MH [83] R4861H CCD [78]
R2163C MH [86, 88, 91, 94] ΔF4863_D4869 CCD [79]
R2163H MH/CCD [85, 88, 91, 94] R4893W CCD [78]
R2163P MH [82] A4894T MH [104]
V2168M MH [86] I4898T CCD [78, 89, 93]
T2206M MH [56] G4899R CCD [78]
N2283H CCD/MmD [99]
N2342S MH [82]
ΔE2347 MH [88]
A2350T MH [58, 96]
RyR2
ΔExon 3 CPVT [115] N2386I ARVD2 [106, 109]
A77V CPVT/ARVD2 [115] R2474S CPVT [48,125,54]
R176Q ARVD2 [106, 126-128] T2504M ARVD2 [106]
R176Q/T2504M ARVD2 [108, 109, 112, 115] N4104K CPVT [19, 118, 119]
E189D CPVT [113] Q4201R CPVT [107, 108, 112]
G230C CPVT [114] R4497C CPVT [19, 68, 71, 72, 105, 118,
119, 123, 124]
R420W ARVD2 [115]
L433P ARVD2 [108, 109, 115] S4565R CPVT [111]
S2246L CPVT [48,50,56-58] V4653F CPVT [107, 112]
R2267H CPVT [111] I4867M CPVT [108]
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Effect Isoform Mutations Disease References Mutations Disease References
P2328S CPVT [52, 54, 55] N4895D CPVT [19]
Hypoactive
RyR1
S71Y/N2283H CCD/MmD [99] I4898T CCD [7,12,13,46,70,73,74, 75]
R109W/M485V CCD/MmD [99, 100] G4899R CCD [87, 100, 103]
C4664R MH [82] G4899E CCD [98, 100]
G4891R CCD [87] A4906V CCD [87]
R4893W CCD [87, 98] R4914G CCD [87]
A4894P CNMDU1 [104] ΔV4927_I4928 CCD [80, 100]
RyR2
L433P ARVD2 [106] A4860G IVF [110, 112]
A1107M CPVT [115]
(T1107M)
Uncertain
effects
RyR1
I403M A1577T/
G2060C
MH/CCD
CCD
[85]
[99]
G3938A (G3938D) MH
MH
[95]
[92]
R2939K MmD [90] D3986A
(D3986E)
RyR2
Table 1. Summary from functional studies on RyR disease-associated mutations. Mutations that alter RyR functions
are listed as hyperactive or hypoactive. Mutations with no discernable change compared with wild type channel are
listed as “uncertain.” References to the functional studies are listed beside the corresponding mutations. (Δ) = deletion
mutation. (/) = double mutation. Amino residue numbering is for human RyRs. (MH) = Malignant hyperthermia, (CCD)
= central core disease, (MmD) = multi-minicore disease, (CNMDU1) = congenital neuromuscular disease with uniform
type 1 fiber, (CPVT) = catecholaminergic polymorphic ventricular tachycardia, (ARVD2) = arrhythmogenic right
ventricular dysplasia type 2, and (IVF) = idiopathic ventricular fibrillation.
The majority of the mutations in both RyR1 and RyR2 have been shown to make the chan‐
nels hyperactive. This includes the first disease-associated mutation found in porcine stress
syndrome, RyR1 R615C. Functional studies have revealed that RyR1 channels with this mu‐
tation have significantly lowered threshold for activation by [Ca2+], caffeine, and halothane
compared to wild-type channels, while having markedly increased threshold for inactiva‐
tion by [Ca2+], Ruthenium Red, or Mg2+ ions [47-52, 101, 116, 117, 129]. These results are char‐
acteristic of mutations that alter RyRs into hypersensitive channels [19, 55-59, 61, 63, 65,
67-69, 71, 73, 76-83, 85-89, 91, 93, 94, 96, 97, 102-109, 111-115, 118, 119]. RyRs that are hyper‐
active are often described as “leaky,” and on top of their increased sensitivity towards acti‐
vators or reduced sensitivity towards inhibitors, they often exhibit increased resting [Ca2+] in
the cytoplasm, reduced SR Ca2+ store content, or altered maximal Ca2+ release.
Although less common, some mutations in RyR have been demonstrated to reduce chan‐
nel activity. [62, 74, 75, 80, 82, 84, 87, 89, 98, 100, 103, 104, 106, 110, 112, 115]. For example,
the I4898T mutation in RyR1, associated with an unusually severe and highly penetrant
form of  CCD,  has  been shown to  cause complete  uncoupling of  sarcolemmal  excitation
from SR Ca2+  release,  in which activating signals from L-type CaV  channels to RyR1 are
uncoupled [84]. It has also been shown that the I4898T mutation leads to a complete loss
of  Ca2+  release  induced  by  caffeine  stimulation  [89].  Many  other  CCD-associated  muta‐
tions  that  are  located  at  the  predicted  pore  region  of  RyR1 (G4890R,  R4892W,  A4894P,
Genetic Disorders114
I4897T, G4898R, G4898E, A4905V, and R4913G) have also been shown to abolish E-C cou‐
pling and/or exhibit reduced sensitivity to activation by [Ca2+], caffeine, or 4-CmC [62, 87,
98, 100, 103, 104]. Mutations that disrupt signaling between the L-type CaV  and RyR are
known as “E-C uncoupling” mutations. In RyR2, fewer mutations have thus far been asso‐
ciated with a reduction in activity, suggesting that a loss of function in RyR2 may be less
tolerated than in RyR1. The A4860G mutation in RyR2 is associated with idiopathic ven‐
tricular  fibrillation  (IVF)  and  is  located  at  the  predicted  inner  pore  helix.  It  has  been
shown to diminish response or increase the threshold for activation by SOICR [110, 112].
Furthermore, the mouse RyR2 A1107M mutation (corresponding to the T1107M mutation
that is  associated with hypertrophic cardiomyopathy in humans) has been shown to in‐
crease the threshold for Ca2+ release termination [115].
Effects of some other disease-associated mutations are less apparent. For instance, single
channel measurements of RyR1 A1577T and G2060C mutant channel produced no discerni‐
ble change in the activity of the channel compared to wild type [99]. Similarly, [3H] ryano‐
dine binding assays of RyR1 R2939K expressed in HEK-293 cells failed to show alteration in
Ca2+ dependence and caffeine activation compared to wild-type channel [90]. In addition,
RyR1 I404M expressed in dyspedic mice myotubes exhibited resting [Ca2+] levels and SR
Ca2+ content comparable to that of the wild type [85]. Furthermore, expressions of RyR1
D3987A and G3939A rabbit cDNA in HEK-293 cells, which correspond to the positions of
MH-associated mutations D3986E and G3938D in humans, respectively, showed responses
to activation by [Ca2+], caffeine, and 4-CmC comparable to that of wild type [92, 95]. For
these mutations where no clear functional effect has been observed, it is of course possible
that they are not causative of the disease but, instead, simply represent polymorphisms. Al‐
ternatively, their effect may only become apparent in the native context, where particular
regulatory mechanisms exist that are not captured by the model systems.
Overall, there is an apparent theme between RyR activity and disease phenotype. MH and
CPVT are associated with RyRs that have an overall gain-of-function phenotype. On the oth‐
er hand, CCD can be due to either a gain or a loss of RyR1 activity. Loss of function results
in impaired Ca2+ release, and hence decreased contractility observed in CCD. The gain of
RyR1 activity can lead to a general “leak“ of Ca2+, resulting in an overall lowered concentra‐
tion of Ca2+ in the SR. The result is then an insufficient amount of Ca2+ being available for an
E-C coupling event, again resulting in decreased contractility.
For those mutations with less clear effects, as well as those which have been shown to be
causative for aberrant Ca2+ homeostasis, combining functional studies with structural inves‐
tigations would provide further useful insight into the molecular basis of disease-associated
mutations in RyRs.
4. Structural studies of RyRs
Structural biology has thrived in recent decades and provides researchers with powerful
tools for exploring all aspects of life. Different structural techniques, covering the resolution
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range from 50 Å down to 1 Å, can reveal the structural details of various bio-molecules,
from large protein/DNA/RNA complex to small peptides, which help to improve our under‐
standing of the physiology and pathology of many biological systems.
However, the large size of the RyR and its membrane protein nature make it a very chal‐
lenging target for structural studies. Most structural techniques require protein samples
with high yield and purity, which is normally achieved by overexpression in recombinant
systems combined with multi-step chromatography purification processes. The large size of
the RyR makes the recombinant expression difficult because the folding of this giant re‐
quires the assistance of many chaperones which are often absent in non-native expression
systems. The differences in the protein trafficking and post-translational modification sys‐
tems may also affect the maturation of the recombinant RyR. The alternative way is to puri‐
fy RyRs from native tissues, but the purification is not easy without artificial affinity tags. To
further complicate the issue, the presence of a large exposed hydrophobic surface in the
transmembrane region requires the addition of detergents to make the protein soluble dur‐
ing the purification. The denaturing property of the detergents usually makes the sample
less homogenous and their presence also affects the crystal packing, both of which are unde‐
sirable for x-ray crystallography. The intrinsic dynamic feature of this multi-domain channel
further increases heterogeneity of the sample and makes it harder to study.
Despite all the technical difficulties, during the last two decades, several structures of RyRs
have been obtained using cryo-electron microscopy (cryo-EM) [130-141], NMR [142] and X-
ray crystallography [143-148]. Some of these structures [142, 143] describe how regulatory
proteins interact with small fragments (peptides) from RyRs and are not relevant to the
theme of this book. Here we will focus on the structures of the full-length channel or large
domains where disease mutations are localized, and show how the structural studies can re‐
veal the molecular mechanism of a genetic disease. More details on the structural insights
into RyR function have been described in a recent review paper [149].
4.1. Cryo-EM studies of RyRs
Electron microscopy has been able to obtain structural information on RyRs at near sub-
nanometer resolution. The early studies using thin-section or negative stain electron micro‐
scopy discovered some "feet" structures (square-shaped densities) in the junction region
between the SR and T-tubules in muscle tissues [150-157]. The identities of these "feet" were
confirmed later when the purified RyRs were imaged by EM, showing similar densities [9].
The negative stain structures with improved resolution revealed that RyRs have a four-fold
symmetry and can interact with four neighbouring molecules to form two-dimensional
checkerboard-like lattices both in native tissue and in vitro [158-162], suggesting that RyRs
may interact cooperatively during gating. The resolution was further improved by the cryo-
EM technique [130-141], in which the protein samples are studied under cryogenic tempera‐
tures. So far the highest resolution reaches 9.6 Å for RyR1 in a reported closed state.
Many  structural  details  can  be  appreciated  from  the  cryo-EM  structures.  The  overall
shape of the RyR is like a mushroom with a large cap in the cytoplasmic domain (27 ×
27 × 12 nm) and a small stem (12 × 12 × 6 nm) crossing the ER/SR membrane. Instead of
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a  single  rigid  block,  the  large  "cap"  consists  of  fifteen  individual  globular  regions  per
subunit  with  many solvent  channels  in  between [163,  164]  (Figure  5A,B).  This  arrange‐
ment maximizes the total exposed surface area, and RyRs thus form perfect scaffolds for
many  small  molecules  and  protein  regulators  to  dock.  The  number  of  transmembrane
(TM) helices in the "stem" is  still  controversial  at  the current resolution.  Five or six TM
helices can be detected in the cryoEM maps [134, 141], but it has been suggested that the
total number should be either 6 or 8 [165]. The last two TM helices create the pore-form‐
ing domain,  which is  homologous  to  the  ones  from tetrameric  potassium channels  and
bacterial sodium channels [141].
Comparison of the RyR structures in the closed and open states reveals movement in both
the "cap" region and "stem" region upon channel gating. An iris-like movement around the
pore switches the channel between dilated and constricted conformations [166] (Figure
5C,D). Samso et al. systematically produced RyR structures in the closed and open states and
found the inner helices in the TM region to kink in the open state, increasing the diameter of
the pore by ~4 Å [132]. However, another group reported that the inner helics are already
kinked in the closed state [141]. The discrepancy can be attributed to differences in sample
preparation. Although the conditions may favor a closed or open channel when the RyR is
in a membrane, this may not be the case after extraction with detergents. In addition, the
amount of oxidation in the sample can also affect the open probability of the channel. It is
therefore possible that the 9.6Å map represents an open, rather than a closed channel, and
this would reconcile the discrepancies between both studies. So far, most cryo-EM studies
are done on RyR1 due to its relatively high abundance. RyR2 and RyR3 have also been stud‐
ied via cryo-EM [137, 138], albeit at lower resolution. The overall folding is similar for all
three isoforms. The major difference between RyR1 and RyR2 is the clamp region on the cor‐
ner of the "cap" [138], while a central domain (possibly corresponding to the residues
1303-1406 in RyR1), which is missing in RyR3, is the most divergent part between RyR1 and
RyR3 [137]. These structural elements very likely contribute to the different properties of the
three subtypes.
The cryo-EM studies of RyRs thus far do not provide the resolution to locate individual resi‐
dues as X-ray crystallography does, but it can give clues about the approximate locations of
individual domains through analysis of the difference densities from insertion of fusion pro‐
teins (such as GFP) or binding of antibodies for the particular domain. The locations of the
three disease hot spots have drawn particular interest since these parts are certainly impor‐
tant for channel function, as the clustering of disease-associated mutations suggests. From
the primary sequence analysis, it is clear that the third hot spot is in the transmembrane re‐
gion ("stem") of the channel. Several insertion studies localize the N-terminal disease hot
spot at the clamp region between the subdomain 5 and 9 [31, 167-169], and the central hot
spot between the subdomain 5 and 6 [170], suggesting that these two hot spots interact with
each other [171] (Figure 5A,B). Similar methods were also used to localize the divergent re‐
gions [172-176] and the phosphorylation sites [177, 178]. The accuracy of these studies varies
depending on the resolution, linker length, insertion site selection and the size of the fusion
protein or antibody. Difference densities analysis was also used to identify the binding sites
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of protein regulators, such as FKBP12/12.6 [133, 179-181], calmodulin [180, 182, 183], chlor‐
ide intracellular channel 2 (CLIC-2) [184] and various toxins [185, 186].
Figure 5. EM maps of RyRs. Top pannels show the top view (A) and side view (B) of the cryo-EM reconstruction of
RyR1 in the closed state at 9.6Å (EMDB accession code 1275) [141]. The structural elements and the subregions are
labeled. Middle pannels show the top view (C) and side view (D) of the superposition of the RyR1 cryo-EM maps in the
closed (gray) and open (cyan) state. (EMDB accession codes 1606 and 1607) [132]. The structural change upon chan‐
nel opening is indicated by the arrows. Bottom panels show a comparison of the transmembrane region of RyR1 in
the open (E) (cyan EMDB accession codes 1606) and closed state (gray EMDB accession codes 1607).
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4.2. X-ray crystallographic studies of RyRs
The crystallization of full-length RyRs is a very challenging task due to its large size, mem‐
brane protein nature and intrinsic flexibility. Improvement in techniques will likely reveal a
high-resolution structure of intact RyRs in the future. The cryo-EM structures have revealed
that the RyR is a large modular protein that consists of many small domains. Many efforts
have therefore been made to crystallize individual domains or domain clusters that carry
important functions.
The first few crystal structures of RyRs that have been solved are of the N-terminal do‐
mains  (domain  A)  in  RyR1  (residues  1-205)  and  RyR2  (residues  1-217)  [144,  145].  Both
display a β-trefoil folding motif (three groups of β-strands that form a triangle structure)
that consists of twelve β strands and contains an extra α helix (Figure 6A,B). Domain A
spans about one third of the N-terminal disease hot spot. A total of 23 and 9 mutations
have  been  found so  far  in  domain  A of  RyR1  and  RyR2,  respectively,  many  of  which
cluster in a loop between β strands 8 and 9. Several disease mutants of this domain have
been analyzed either by NMR or x-ray crystallography, but none of them showed major
structural  changes [144,  145]  (Figure 7A,B).  The observation that  most  mutations are lo‐
cated on the surface of  domain A indicates that  they likely affect  the interaction of  do‐
main A with other domains in RyR or auxiliary proteins.
A severe form of CPVT is caused by the deletion of the entire exon 3 (residues 57-91) from
the ryr2 gene [187, 188]. The structure of wild type domain A shows that exon 3 contributes
to a loop region, the 310 helix, β4 strand, and the α helix. One would expect that the complete
absence of these structural elements will cause the misfolding of the domain and a loss-of-
function phenotype. However, surprisingly, Δexon 3 is not strictly lethal. CPVT symptoms
and functional studies suggest a gain-of-function phenotype instead [115]. Even more sur‐
prising, the mutant has a higher thermal stability compared to the wild type domain [145].
A crystal structure of RyR2 domain A with Δexon 3 revealed an unusual "structural rescue"
scheme: a flexible loop following the exon 3 region replaces the deleted β4 strand and re‐
sults in a similar overall fold of the domain [147] (Figure 7C). The α helix, however, is lost.
The ability to "rescue" a β strand with a random loop segment is highly unusual and sug‐
gests that there has been evolutionary pressure to maintain the exact sequence of the flexible
loop. Most likely, there is the possibility of alternative splicing, whereby exon 3 is naturally
spliced in some cell types. This would represent a mechanism whereby the RyR activity can
be fine-tuned in a tissue-specific manner [147]. So far, such a splice variant has not yet been
reported.
Up to now, the largest reported crystal structure for all RyRs is for the N-terminal three do‐
mains (domain A, B and C, residues 1-559) of RyR1, which covers the majority of the N-ter‐
minal disease hot spot [146]. It shows a triangular arrangement of the three domains that
interact with each other, mainly through hydrophilic interfaces. Domains A and B have sim‐
ilar β-trefoil folding motifs, while domain C has an armadillo-repeat structure consisting of
a bundle of five α-helices (Figure 6C). A total of 76 mutations (RyR1+RyR2) have been iden‐
tified in these domains. 17 of these are localized at the interfaces between domains A, B and
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C (within one subunit). 9 mutations are buried inside the individual domains, and the re‐
maining are on the surface of the ABC structure.
Figure 6. Crystal structures of RyR N-teminal hot spot domains. Shown are crystal structures of (A) RyR1 domain A
(pdb: 3ILA), (B) RyR2 domain A (pdb: 3IM5), and (C) RyR1 domain ABC (pdb: 2XOA). α-helices and β-sheets are shown
in dark and light colors, respectvely. RyR1 and RyR2 mutations are mapped on the strutural models, indicated by black
sticks, and labeled. RyR2 mutations are distinguished from RyR1 mutations by *. Deletion mutations are labeled by Δ.
The numbering is according to human RyR1 and RyR2 sequences. The N-terminal and C-terminal positions of the
structures are labeled with Nt and Ct, respectively.
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Although the EM structure itself usually does not provide the resolution to resolve the
atomic positions, the combination of crystal structures and EM structures allows pseudo-
atomic models to be built. Individual amino acid residues can thus be located within the
overall 3D structure. The high-resolution crystal structures can be docked into the EM maps
by matching their electron densities using complex 6 dimensional search algorithms
[189-191]. The confidence of the solutions depends on the quality of the EM map, the size of
the docked fragments and the agreement of conformations from the two structures. Some‐
times a Laplacian filter, which uses an edge-detection algorithm to increase the sensitivity
can increase the success rate when a small fragment is used as a search model [191]. Docking
of the RyR1 ABC crystal structure into three different cryo-EM maps places it at the same
location, the central rim region, forming a cytoplasmic vestibule around the four-fold sym‐
metry axis (Figure 10) [146]. This solution contradicts previous results from insertion experi‐
ments which localize the N-terminal hot spot at the clamp region near the corner [167, 168].
The authors suggested that in the GFP-insertion study [168] the long linker and the native
flexible loop make it possible for the inserted GFP to be present in a remote location [146]. In
addition, the difference density observed in a GST-insertion study splits into two regions,
one of which is indeed right beside the central rim region [167]. Interestingly, the location
and orientation of domains ABC from the IP3 receptor, a closely related Ca2+-release channel,
are remarkably similar to the docking solution of RyR1 ABC, which further validates the lo‐
cation of the N-terminal region [192].
Locating  the  N-terminal  region  within  intact  RyRs  allows  several  new  interfaces  to  be
identified. As the ABC domains dock near the 4-fold symmetry axis, there is a direct in‐
teraction between domains A and B from neighboring subunits (Figure 10).  In addition,
there are five other interfaces between the ABC domains and other regions of RyR1. All
the peripheric  disease mutations identified in domains ABC are located in one of  these
six  interfaces  and  none  of  them  are  exposed  to  the  surface  of  the  full-length  channel,
suggesting that  they mainly  affect  the  inter-domain interactions  rather  than interactions
between the RyR and other proteins.
The activity of RyRs can be regulated by different types of kinases and phosphotases (Figure
1 and 2). It is believed that the chronic hyperphosphorylation of RyR2 by PKA can dissociate
the binding of FKBP12.6 and cause heart failure [193-195], although this result has not been
confirmed by other laboratories [118, 196, 197]. Two recent papers reported the structures of
a domain containing the phosphorylation sites from all three RyR isoforms [148], and from
RyR1 [198] (Figure 8A,B,C). The domain consists of two symmetric halves. Each half con‐
tains two α helices, one or more short 310 helices, and a C-terminal β strand. Multiple phos‐
phorylation sites were identified in this domain of RyR2 [148] and most cluster within the
same loop. The RyR2 domain doesn’t contain any reported disease mutations, but up to 11
disease mutations are found in the RyR1 domain. Interestingly, several disease mutations
from this domain are also located close to the phosphorylation sites, suggesting that phos‐
phorylation and disease mutations at this site may have the same effect (Figure 8A). One
mutation, L2867G, reduces the melting temperature of the individual domain by 13°C and
causes the aggregation of the domain at room temperature (Figure 7D). Several crystal struc‐
Structural Insights Into Disease Mutations of the Ryanodine Receptor
http://dx.doi.org/10.5772/53641
121
tures for the other disease mutants were also reported in this study, showing that they affect
surface properties and intradomain salt bridges (Figure 7E,F,G) [148]. Docking into the EM
map places this domain in the clamp region, but none of the neighbouring domains have
been identified thus far (Figure 10). Solving structures of other domains may place more
pieces into this big jigsaw and increase our understanding of the isolated domains.
Figure 7. Disease mutant crystal structures. Superposition of the wild-type RyR domains (white) with the mutant struc‐
tures (colors). Atoms are color coded, with nitrogens in blue, oxygens in red, and sulfurs in yellow. Hydrogen bonds
are indicated by dashed lines. All mutants are from RyR1 except the Δexon3 mutant (C) which is from RyR2. (A) A77V,
(B) V186M, (C) Δexon3, (D) L2867G mutant (only wild-type structure shown), (E) E2764K, (F) S2776M, (G) R2939S. The
single residue mutations are indicated in black. In panel (C), exon 3 is shown in green, and the flexible loop that repla‐
ces exon 3 in Δexon3 structure (pdb: 3QR5), is shown in red.
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Figure 8. Crystal structures of RyR phosphorylation domains. (A-C) RyR1-3 phosphorylation (tandem repeats 2) do‐
mains (pdb: 4ERT, 4ETV, 4ERV, respectively). The phosphorylation loops in RyR1/2 and the corresponding loop in RyR3
are missing in the crystal structures, and indicated by dashed lines in the figures. α-helices and β-sheets are shown in
dark and light colors, respectvely. RyR1 mutations are mapped on the strutural models, indicated by black sticks, and
labeled. The numbering is according to human RyR1 sequence. The N-terminal and C-terminal positions of the struc‐
tures are labeled with Nt and Ct, respectively.
4.3. Homology models for RyR domains
So far all the available crystal structures cover ~15% of the full-length RyR in total. There is
still a big portion missing. One alternative way to obtain structural informaiton is to create
homology models based on known structures using bioinformatics methods. Generally the
reliability of a homology model depends on the sequence identities between two proteins,
but protein 3D structures tend to be more conserved than their primary sequences during
evolution [199]. As the largest ion channel, the evolution of modular RyRs involves the in‐
corporation, loss and duplication of different domains. Protein sequence analysis identifies
several domains that are present multiple times in RyR genes, including SPRY domains and
tandem repeat domains.
The spore lysis A and RyR (SPRY) domains have been found in many different proteins
from bacteria, archaea, viruses and eukaryotes. They are generally known as protein interac‐
tion domains [200]. There are three SPRY domains identified in metazoan RyR genes
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(SPRY1,2,3) (Figure 3). In skeletal muscle, RyR1 (located in the SR membrane) and CaV1.1
(located in the plasma membrane) are thought to interact directly. Some biochemical evi‐
dence suggest that the RyR1 SPRY2 domain forms an interaction with one of the intracellu‐
lar loops of CaV1.1, the so-called II-III loop [201]. Using the phyre2 engine [202], we built
homology models for all three SPRY domains of RyR1, based on several known SPRY pro‐
tein structures (Figure 9A,B,C). All these models show a signature β-sandwich (two stacked
β-sheets) folding motif. Interestingly, all ten disease mutations identified in these three
SPRYs are located peripherally when mapped into the models (Figure 9A,B,C). As before, it
seems that mutations cluster at the surfaces of individual domains, likely affecting interac‐
tions with neighboring domains or RyR binding partners. This observation agrees with the
known protein interacting properties of the SPRY domain. The mutations in these domains
may weaken the interaction with other domains or proteins and change the channel activi‐
ties.
Another domain fold present in RyRs is the so-called "RyR domain". The latter name is un‐
fortunate, as it obviously is not the only domain present in RyRs. These domains are ar‐
ranged in tandem repeats, and we will hereafter refer to them as "tandem repeat domains".
Each repeat unit is about 100 residues in length, and there are two tandem repeats within
each human ryr gene: one between SPRY1 and SPRY2, and the other at the central region
(Figure 3). These repeat units are also present in bacteria, archaea and viruses, either in sin‐
gle form or in pair with itself or other proteins [203]. The phosphorylation domain men‐
tioned above makes up the second tandem repeat [148]. Interestingly, in a crystal structure
of a bacterial repeat domain (pdb code: 3NRT), a single domain dimerizes and presents a
similar fold as the paired repeat domain shown in the phosphorylation domain structure.
We created a homology model for the first tandem repeats from RyR1 based on these two
protein structures [202]. (Figure 9D). Seven mutations are found on this tandem repeat. Five
of these are located on the surface, likely affecting interactions with other domains or RyR
binding partners. The remaining two are buried within the domain, and may thus affect the
overall folding stability.
Although the total number of the TM helices in RyRs is not clear, from the secondary struc‐
ture prediction, their last two TM helices clearly share homology with the pore-forming re‐
gions of potassium channels and bacterial voltage-gated sodium channels (NaV). Because the
pore-forming region is directly responsible for passage of Ca2+ ions through the SR mem‐
brane, any minor structural alteration in this region may directly interfere with the ion con‐
duction. Indeed, up to 50 mutations (RyR1+RyR2) have been identified in this region, which
consists of only 125 residues. The occurrence of one mutation per 2.5 residues makes the
pore-forming region into a "super-hot" disease hot spot. We created a model for the RyR1
pore-forming domain based on several bacterial NaV structures (Figure 9E). Most mutations
cluster in the top half (ER luminal side) of the domain. Interestingly, 31 out of 41 RyR1 mu‐
tations in this domain are associated with CCD, which can be caused by the loss-of-function
of RyRs. Therefore, it seems that many mutations in the TM domain can directly block the
ion conduction pathway and reduce channel activity, while mutations in the cytoplasmic
domains tend to destabilize the closed state of the channel and make it "leaky".
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Figure 9. Homology structural models of RyR domains. Structural models were created by Phyre2 server [202]: (A-C)
RyR1 SPRY 1-3, (D) RyR1 repeats 1, and (E) RyR1 pore-forming domain (PF). α-helices and β-sheets are shown in dark
and light color, respectvely. RyR1 and RyR2 mutations are mapped on the strutural models, indicated by black sticks,
and labeled. RyR2 mutations are distinguished from RyR1 mutations by *. Deletion mutations are labeled by Δ and
insertion mutations are labeled by ins. The numbering is according to human RyR1 and RyR2 sequences. The N-termi‐
nal and C-terminal positions of the structures are labeled with Nt and Ct, respectively.
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Like the previous studies with crystal structures, knowing the exact locations of these do‐
mains in the full length channel will deepen our understanding of the channel in the normal
and disease states. But technically it is dangerous to dock homology models into the EM
maps due to their limited accuracy. However, these models can still provide a good tem‐
plate to guide the design of the insertion sites for the EM studies, which will help to reveal
the location of these domains and the corresponding disease mutations.
Figure 10. Pseudo-atomic models. Top view of the 9.6 Å RyR1 cryo-EM map (EMDB accession code 1275), showing the
docked positions of the N-terminal disease hot spot (domain A (blue), B(green), C(red)) and the phosphorylation do‐
main (purple) [141].
5. Conclusion
The available crystal structures and homology models represent ~32% of the full length
RyRs. In the years to come, further crystallographic studies on predicted domains, and their
localization into full-length RyRs will likely shed more light. Although obtaining well-dif‐
fracting crystals of intact RyRs may be an arduous task, this will ultimately be necessary to
fully understand the function of RyRs in health and disease.
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